Stratasys (NASDAQ:SSYS) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings

Stratasys (NASDAQ: SSYS) reported Q2 CY2026 revenue of $137.6 million, flat year on year and slightly below Wall Street estimates, according to the company. Full-year revenue guidance was $570 million at the midpoint, near analyst expectations. Non-GAAP EPS was $0.03, above consensus by $0.02, and analysts expect full-year EPS to rise from $0.11 to $0.16.

Original reporting
Published Aug 13, 2026, 2:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 2:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stratasys (NASDAQ:SSYS) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings — source image
Decision brief

The 30-second read

$SSYSNeutralMed
01

Why it matters

Q2 revenue came in slightly below expectations while EPS beat; FY revenue guidance was close to consensus, suggesting limited upside surprise but continued monitoring of demand and margin trajectory.

02

Market read

Traders can reassess near-term demand risk versus cost/profitability progress after the Q2 print and FY revenue midpoint guidance.

03

What to watch

The article emphasizes long-term decline and negative operating margins, but does not quantify backlog, order intake, or contract wins that could explain the revenue softness.

Relevance 7/10Novelty 6/10Timing: post-Q2 results, same-day reaction

Background

Stratasys is a 3D printing hardware and services provider, with revenue split between Products and Services.

Company-level read

Ticker impact

$SSYSNeutralMedium confidence
Context

Stratasys reported Q2 CY2026 revenue of $137.6M, flat YoY, slightly below analyst expectations, while guiding FY revenue to $570M midpoint.

Expected impact

Short-term bias neutral to slightly negative unless investors focus on the EPS beat and FY guide midpoint.

Evidence & confidence

The article provides a concrete Q2 revenue miss and FY revenue guidance near consensus, plus an EPS beat; without new guidance surprises, the net effect is likely limited and sentiment-dependent.

Market effects

Signals ongoing demand softness in industrial 3D printing, with profitability still pressured by negative operating margins.

No specific regional impact described.

No explicit global macro or supply-chain shock cited.

Counterpoint

Investors may treat the EPS beat and EBITDA outperformance as evidence of improving cost discipline, using the revenue miss as a temporary timing issue.

Key entities

  • Stratasys

    Reported Q2 CY2026 revenue of $137.6M (flat YoY) and guided FY revenue to $570M midpoint; adjusted EPS $0.03 beat consensus.

Related articles

$SSYSHighAI 9/10

Stratasys To Buy Markforged For $42.5 Mln To Expand Defense, Aerospace Offering

Stratasys (SSYS) agreed to buy Markforged in an all-cash deal valued at $42.5 million to expand its defense and aerospace 3D-printing offerings, adding Markforged’s continuous carbon fiber technology and Digital Forge software. Stratasys expects margin and EBITDA accretion within one year after closing, with cost synergies, and will update guidance post-close. The deal is expected to close in H2 2026.

$GSKMed

Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?

GSK plc reported Q2 results on July 28. Total turnover was £8.4bn, up 5% CER. Core operating profit rose 7% CER to £2.80bn and Core EPS increased 9% CER to 50.5p, driven by Specialty Medicines and Vaccines. Total operating profit fell 75% CER due to a £1.3bn non-cash impairment after discontinuing camlipixant. GSK also outlined a 2026 Phase III acceleration plan and a £1.9bn annual cost-savings restructuring program.

$BFRIMedAI 8/10

Biofrontera Posts Strong Q2 2026 Results On 33% Revenue Growth

Biofrontera (BFRI) reported Q2 2026 net product revenue of $12.0M, up 32.9% from $9.0M, with gross margin rising to 80% from 71%. Net loss narrowed to $0.6M from $5.3M. For six months, revenue was $22.1M (+25.4%) and gross margin 80%. A PDUFA decision for Ameluz is expected Sept. 28, 2026.

$UPWKMedAI 8/10

Why Upwork (UPWK) Stock Is Nosediving

Upwork (UPWK) shares fell about 10% after the company reported Q2 results that beat estimates but issued weaker full-year revenue and EPS guidance. Analysts at Scotiabank and RBC cut price targets to $10 and $9 from $15 and $20, respectively, while keeping Sector Perform ratings. The stock is down sharply year to date amid AI and labor-market concerns.

$ARMKMedAI 8/10

Why Aramark (ARMK) Stock Is Up Today

Aramark (NYSE:ARMK) shares rose about 9.8% after the company reported better-than-expected Q3 2026 results. Revenue was $5.06B, up 9.3% year over year, and adjusted EPS was $0.52 above consensus. Free cash flow turned positive at $8.69M versus a $33.55M loss a year earlier.